MAOB and glioblastoma: Since glutamate–MAO-B activity was demonstrated to be a mediator for astrogliosis and scar formation (Fig. 3e-k), we investigated whether the astrocytic scar targeting GBM-microglia assembloid would be inhibited upon treatment with glutamate transporter inhibitor (100 μM TBOA) and/or MAO-B inhibitor (1 μM KDS2010).